

REMARKS

Requirement for Restriction/Election

In the Requirement for Restriction/Election dated June 23, 2006, pending claims 1, 2, 4-7, 10-12, 14, 28, 32, **55***, 73 and 77-82 were restricted under 35 U.S.C. §121 into the following five groups:

- I. Claims 1, 2, 4-7, 10, 11, 12, and 14, drawn to a method of modifying an initial antibody, a library of nucleic acids produced by said method, and one or more recombinant cells comprising one or more members of said library, classified in class 435, subclass 4, with an additional requirement for a species election.
- II. Claims 28 and 32, drawn to methods of evolving HIV envelope protein with improved antigenicity and the resultant envelope protein, classified in class 435, subclass 4.
- III. Claim 55*, drawn to a method of providing a population of recombinant anti-enterotoxin monoclonal antibody nucleic acids, classified in class 435, subclass 4.
- IV. Claims 73 and 77-81, drawn to a method for modifying the effector function of an antibody, classified in class 435, subclass 4.
- V. Claim 82, drawn to a method of humanizing an antibody, classified in class 435, subclass 4.

* Applicants wish to point out that pending claim 55 was not included in the Office Action Summary page under either item 4 (claims pending in the application) or item 8 (claims subject to restriction and/or election requirement).

Election

Applicants hereby elect Group IV claims 73 and 77-81 for prosecution in this application, without traverse.

Erik Karrer, *et al.*
Application No.: 10/686,945
Filed: Oct. 16, 2003
Response to Restriction Requirement
page 5 of 5

Attorney Docket No.: 0241us320

Status of the Claims

Group I claims 1-2, 4-7, 10-12, and 14; Group II claims 28 and 32; Group III claim 55; and Group V claim 82 are canceled herein as being drawn to non-elected restriction groups, without prejudice to filing in one or more continuation and/or divisional applications. Claims 3, 8-9, 13, 15-27, 29-31, 33-54, 56-72, 74-76, and 83-88 were canceled, without prejudice to renewal in the instant application or to filing in one or more continuation and/or divisional applications, in the Preliminary Amendment submitted October 27, 2004. Please note that Applicants reserve the right to file subsequent applications claiming any canceled subject matter, and that the claim cancellations should not be construed as abandonment of any claimed subject matter.

Claims 73 and 77-81, drawn to Restriction Group IV, are pending with entry of this amendment.

CONCLUSION

If a fee is due beyond that for the four-month extension of time, the Commissioner is authorized to charge the fee to Deposit Account No. 50-0990. Please charge any additional fees which may be due, or credit any overpayment, to Deposit Account No. 50-0990.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (650) 298-5452.

Respectfully submitted,

November 22, 2006



Joanne R. Petithory, Ph.D.
Reg. No. 42,995

Maxygen, Inc.
Intellectual Property Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560